finance

money stack
Biotech

Big biotech venture funds raise billions despite coronavirus fears

By Matthew Herper and Kate Sheridan

doc entering er dept.
Health

Amid coronavirus, private equity-backed company slashes benefits for emergency room doctors

By Lev Facher

Video Chat

STAT Plus video chat: Biotech in uncharted territory

By Adam Feuerstein and Matthew Herper

NYSE - 3/16
First Opinion

The economic rationale for strong action now against Covid-19

By Mireille Jacobson and Tom Chang

Stock Market Down
Biotech

As the market craters, Keros Therapeutics files for an IPO

By Kate Sheridan

coronavirus/toilet paper
First Opinion

The novel coronavirus is a serious threat. We need to prepare, not overreact

By Darren Schulte

T-cell lymphoma
Biotech

Kymera announces $102 million in new funding to develop treatments for diseases such as blood cancers

By Anissa Gardizy — Boston Globe

doctor's waiting room
Politics

Private equity firms are increasingly buying up doctors’ offices. What does that mean for doctors — or for patients?

By Lev Facher

gene therapy
Biotech

This biotech went public during the stock market’s worst week since 2008

By Kate Sheridan

Something ventured illo
Something Ventured

Something Ventured: Vor Biopharma and 3 other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

Big fish
First Opinion

Physician practice consolidation: It’s only just begun

By Praveen Suthrum

Cambridge: AbbVie
Pharmalot

Consumer groups and unions try again to block the AbbVie and Allergan merger

By Ed Silverman

STAT Summit 2019
STAT Summit

Watch: VCs have to predict the future. Here’s what three of them expect next in biotech

By STAT staff

Biotech

Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows

By Kate Sheridan

NASDAQ
Biotech

A longtime health care investor recalls the insulin bong, praises discipline in valuations, and looks to South America

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Play
The Readout LOUD

Listen: The Zolgensma lottery, billionaire philanthropy, & life on the buy side

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

DNA Editing
Biotech

Beam Therapeutics raises $180 million in IPO

By Jonathan Saltzman — Boston Globe

Jorge Conde Andreessen Horowitz
Exclusive

This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund

By Erin Brodwin

Daniel O'Day STAT Summit
STAT Summit

Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?

By STAT staff

Missing women
Biotech

Three star scientists announce plan to solve biotech’s ‘missing women’ problem

By Sharon Begley

2018 biotech outlook: Sunrise
Biotech

Biotech earnings preview: Unsettled investors hoping for strong 2020 outlooks

By Adam Feuerstein

Sperm motility illustration
Biotech

‘The gurus of sperm’: Ohana Biosciences is taking a different approach to fertility 

By Kate Sheridan

23andMe kits
Business

23andMe laying off 14% of employees amid slump in DNA spit kit sales

By Erin Brodwin

Drug pricing transparency
Pharmalot

Many patient groups have deep ties to pharma but fail to disclose backing

By Ed Silverman

Brain neurons
Biotech

A venture firm warms to funding neuroscience

By Matthew Herper

Patrick Soon-Shiong
Biotech

After a single patient drives a big stock surge, Patrick Soon-Shiong makes his case to investors

By Rebecca Robbins

Pharmalot

Pharmalittle: Roche plans aggressive SMA drug pricing; where are those clinical trial results?

By Elizabeth Cooney

SHATTERED DIGIPILL
Exclusive

A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels

By Rebecca Robbins

JPM 2020 Lombard St
Adam's Take

All talk, no M&A makes for a down JPM Day

By Adam Feuerstein

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy